摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(3-nitrothiophen-2-yl)oxazole | 1239463-92-3

中文名称
——
中文别名
——
英文名称
2-(3-nitrothiophen-2-yl)oxazole
英文别名
2-(3-nitrothiophen-2-yl)-1,3-oxazole
2-(3-nitrothiophen-2-yl)oxazole化学式
CAS
1239463-92-3
化学式
C7H4N2O3S
mdl
——
分子量
196.186
InChiKey
GGKGBQLXHGQLLL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.5
  • 重原子数:
    13
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    100
  • 氢给体数:
    0
  • 氢受体数:
    5

反应信息

  • 作为反应物:
    描述:
    2-(3-nitrothiophen-2-yl)oxazole 在 palladium 10% on activated carbon 、 氢气 作用下, 以 乙酸乙酯 为溶剂, 50.0 ℃ 、275.8 kPa 条件下, 生成 2-(oxazol-2-yl)thiophen-3-amine
    参考文献:
    名称:
    Design and synthesis of disubstituted thiophene and thiazole based inhibitors of JNK
    摘要:
    From high throughput screening, we discovered compound 1, the prototype for a series of disubstituted thiophene inhibitors of JNK which is selective towards closely related MAP kinases p38 and Erk2. Herein we describe the evolution of these compounds to a novel class of thiophene and thiazole JNK inhibitors that retain favorable solubility, permeability, and P-gp properties for development as CNS agents for treatment of neurodegeneration. Compound 61 demonstrated JNK3 IC(50) = 77 nM and retained the excellent broad kinase selectivity observed for the series. (C) 2010 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2010.10.066
  • 作为产物:
    参考文献:
    名称:
    Inhibitors of Jun N-terminal kinase
    摘要:
    本公开提供具有以下式子结构的c-Jun N末端激酶(JNK)抑制剂:或其盐或溶剂,其中环A,Ca,Cb,Z,R5,W和Cy在此定义。本公开还提供包括本公开化合物的药物组合物,以及使用本公开化合物和组合物的方法,例如在治疗和预防各种疾病中,如阿尔茨海默病。
    公开号:
    US09073891B2
点击查看最新优质反应信息

文献信息

  • [EN] INHIBITORS OF JUN N-TERMINAL KINASE<br/>[FR] INHIBITEURS DE L'ENZYME JUN N-TERMINAL KINASE
    申请人:ELAN PHARM INC
    公开号:WO2010091310A1
    公开(公告)日:2010-08-12
    The present disclosure provides inhibitors of c-Jun N-terminal kinases (JNK) having a structure according to the following formula (I): or a salt or solvate thereof, wherein ring A, Ca, Cb, Z, R5, W and Cy are defined herein. The disclosure further provides pharmaceutical compositions including the compounds of the present disclosure and methods of making and using the compounds and compositions of the present disclosure, e.g., in the treatment and prevention of various disorders, such as Alzheimer's disease.
    本公开提供了具有以下结构的c-Jun N-末端激酶(JNK)抑制剂(I)的结构,或其盐或溶剂化物,其中环A,Ca,Cb,Z,R5,W和Cy在此处定义。本公开还提供了包括本公开化合物的药物组合物,以及制备和使用本公开化合物和组合物的方法,例如在治疗和预防各种疾病,如阿尔茨海默病。
  • INHIBITORS OF JUN N-TERMINAL KINASE
    申请人:SHAM Hing L.
    公开号:US20130072494A1
    公开(公告)日:2013-03-21
    The present disclosure provides inhibitors of c-Jun N-terminal kinases (JNK) having a structure according to the following formula: or a salt or solvate thereof, wherein ring A, C a , C b , Z, R 5 , W and Cy are defined herein. The disclosure further provides pharmaceutical compositions including the compounds of the present disclosure and methods of making and using the compounds and compositions of the present disclosure, e.g., in the treatment and prevention of various disorders, such as Alzheimer's disease.
    本公开提供了具有以下结构的c-Jun N端激酶(JNK)抑制剂: 或其盐或溶剂,其中环A、Ca、Cb、Z、R5、W和Cy在此被定义。本公开还提供了包括本公开化合物的药物组合物以及制备和使用本公开化合物和组合物的方法,例如,在治疗和预防各种疾病,如阿尔茨海默病中使用。
  • Inhibitors of Jun N-Terminal Kinase
    申请人:Sham Hing L.
    公开号:US20100331335A1
    公开(公告)日:2010-12-30
    The present disclosure provides inhibitors of c-Jun N-terminal kinases (JNK) having a structure according to the following formula: or a salt or solvate thereof, wherein ring A, C a , C b , Z, R 5 , W and Cy are defined herein. The disclosure further provides pharmaceutical compositions including the compounds of the present disclosure and methods of making and using the compounds and compositions of the present disclosure, e.g., in the treatment and prevention of various disorders, such as Alzheimer's disease.
    本公开提供抑制c-Jun N-末端激酶(JNK)的抑制剂,其结构符合以下公式:其中环A、Ca、Cb、Z、R5、W和Cy在此定义。本公开还提供包括本公开化合物的药物组合物以及制备和使用本公开化合物和组合物的方法,例如在治疗和预防各种疾病,如阿尔茨海默病中的应用。
  • US8450363B2
    申请人:——
    公开号:US8450363B2
    公开(公告)日:2013-05-28
  • US9073891B2
    申请人:——
    公开号:US9073891B2
    公开(公告)日:2015-07-07
查看更多

同类化合物

锡烷,1,1'-(3,3'-二烷基[2,2'-二噻吩]-5,5'-二基)双[1,1,1-三甲基- 试剂5,10-Bis((5-octylthiophen-2-yl)dithieno[2,3-d:2',3'-d']benzo[1,2-b:4,5-b']dithiophene-2,7-diyl)bis(trimethylstannane) 试剂2,2'-Thieno[3,2-b]thiophene-2,5-diylbis-3-thiophenecarboxylicacid 试剂1,1'-[4,8-Bis[5-(dodecylthio)-2-thienyl]benzo[1,2-b:4,5-b']dithiophene-2,6-diyl]bis[1,1,1-trimethylstannane] 苯并[b]噻吩,3-(2-噻嗯基)- 聚(3-己基噻吩-2,5-二基)(区域规则) 甲基[2,3'-联噻吩]-5-羧酸甲酯 牛蒡子醇 B 噻吩并[3,4-B]吡嗪,5,7-二-2-噻吩- 噻吩[3,4-B]吡嗪,5,7-双(5-溴-2-噻吩)- 十四氟-Alpha-六噻吩 三丁基(5''-己基-[2,2':5',2''-三联噻吩]-5-基)锡 α-四联噻吩 α-六噻吩 α-五联噻吩 α-七噻吩 α,ω-二己基四噻吩 5,5′-双(3-己基-2-噻吩基)-2,2′-联噻吩 α,ω-二己基六联噻吩 Α-八噻吩 alpha-三联噻吩甲醇 alpha-三联噻吩 [3,3-Bi噻吩]-2,2-二羧醛 [2,2’]-双噻吩-5,5‘-二甲醛 [2,2':5',2''-三联噻吩]-5,5''-二基双[三甲基硅烷] [2,2'-联噻吩]-5-甲醇,5'-(1-丙炔-1-基)- [2,2'-联噻吩]-5-甲酸甲酯 [2,2'-联噻吩]-5-乙酸,a-羟基-5'-(1-炔丙基)-(9CI) IN1538,4,6-双(4-癸基噻吩基)-噻吩并[3,4-C][1,2,5]噻二唑(S) C-[2,2-二硫代苯-5-基甲基]胺 6,6,12,12-四(4-己基苯基)-6,12-二氢二噻吩并[2,3-D:2',3'-D']-S-苯并二茚并[1,2-B:5,6-B']二噻吩-2,8-双三甲基锡 5’-己基-2,2’-联噻吩-5-硼酸频哪醇酯 5-辛基-1,3-二(噻吩-2-基)-4H-噻吩并[3,4-c]吡咯-4,6(5H)-二酮 5-苯基-2,2'-联噻吩 5-溴5'-辛基-2,2'-联噻吩 5-溴-5′-己基-2,2′-联噻吩 5-溴-5'-甲酰基-2,2':5'2'-三噻吩 5-溴-3,3'-二己基-2,2'-联噻吩 5-溴-3'-癸基-2,2':5',2''-三联噻吩 5-溴-2,2-双噻吩 5-溴-2,2'-联噻吩-5'-甲醛 5-氯-5'-苯基-2,2'-联噻吩 5-氯-2,2'-联噻吩 5-正辛基-2,2'-并噻吩 5-己基-5'-乙烯基-2,2'-联噻吩 5-己基-2,2-二噻吩 5-全氟己基-5'-溴-2,2'-二噻吩 5-全氟己基-2,2′-联噻吩 5-乙酰基-2,2-噻吩基 5-乙氧基-2,2'-联噻吩 5-丙酰基-2,2-二噻吩